linkedin

Press Releases

Samsung BIO Insight

Samsung Biologics 2021 Year in Review

#2021YearinReview
 

 

2021 was a year to reflect on the decade of immense growth and innovation as we celebrated our 10-year anniversary. We continued with our efforts to supply high-quality biomedicines to patients and embarked upon an important mission to manufacture COVID-19 therapies and mRNA vaccines for both drug product and drug substance to combat the global pandemic to save people’s lives.

 

As the most trusted CDMO partner to our clients, we have accomplished a number of outstanding achievements and here are some of the key highlights that shaped an extraordinary year.

 

 

#TheFutureofBiopharma


At the 2021 JP Morgan Healthcare Conference, we shared our vision for the next decade, unveiling a multi-dimensional business plan for the company with a greater global footprint and continued advancements in future modalities. 

 

By embracing great opportunity ahead of us, we have strived this year to diversify our portfolio to become the global top-tier biopharmaceutical company. 

 

#TheFutureofBiopharma
 

 

Samsung Biologics Shares ‘Vision’ for Next Decade at the 39th Annual JP Morgan Healthcare Conference
John Rim, CEO of Samsung Biologics shares future plans at BIO Digital 2021
CPhI Worldwide 2021 I Infinite Possibilities for the Next Decade
Talking COVID-19 Vaccine Cooperation with John Rim
BBC Storyworks | The Speed of Science

 

 


#mRNA 


mRNA was without a doubt the most talked about topic this year in turning the tide of the pandemic.

 

We began the supply of Moderna’s COVID-19 vaccine (mRNA 1273) upon securing the large-scale commercial fill-finish manufacturing agreement and successfully obtained Marketing Authorization from Ministry of Food and Drug Safety of Korea within 7 months of signing.

In November, we also announced the collaboration to manufacture GreenLight’s mRNA COVID-19 vaccine candidate at commercial scale, aiming to open the way to make vaccines available to everybody, including patients in lower income countries.

 

With our commitment to save lives by creating greater accessibility to biomedicines worldwide, this year we made an announcement to add messenger RNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022.

 

#mRNA


 

Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing

 



#ESG

 

This year, sustainability was not just a buzzword – it was our mission and commitment.

 

To create a sustainable future for humanity, we published our first sustainability report, consolidating a roadmap to building a more sustainable environment for all.

In September, we announced the signing of an MOU to participate in the Frontier -1.5D initiative to develop a climate risk management model as part of the 2050 Carbon Neutral Strategy in response to the ongoing challenges associated with global climate change.

 

We also joined leaders across the healthcare system to form a Health Systems Taskforce as part of the Sustainable Markets Initiative hosted by His Royal Highness Prince of Wales in light of COP26. Within the Taskforce, John Rim, CEO of Samsung Biologics, was designated as a champion for the Supply Chains Working Group with a focus on accelerating the net zero transition across the health system’s supply chains by establishing concrete action plans and metrics to assess its environmental impact.

 

We are committed to making sustainability a key component of the way we work and engage with our partners and stakeholders, and will continue to actively partake in this global movement next year.

 

Sustainability Report 2021
 
 

 

Samsung Biologics Issues First Annual Sustainability Report
Sustainable Markets Initiative(SMI) | CEO Message
Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative
Six Korean companies added to Dow Jones Sustainability World Index

 

 


#Quality


Despite the ongoing spread of COVID-19, we established a robust internal system to stably supply biomedicines to patients. Over the course of this year, we added five global ISO certifications for ISO22301 BCMS(Business Continuity Management System▲ISO45001 Occupational Health and Safety ▲ISO14001 Environmental Management ▲ISO50001 Energy Management ISO9001 Quality Management System.

 

Also amid a time of significant changes to the market dynamics, we proactively implemented innovative digitalized tools into our processes to enhance the client experience. By leveraging our Live Virtual Tour, EQUIS: Enterprise Quality Unified Information System, and virtual exhibition hall, our employees worked tirelessly to improve our service offerings and ultimately provide top-notch quality biomedicines.

 

#Quality
 

 

Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health & Safety, and Environmental Management
Samsung Biologics adds to global ISO certifications with Quality Management System
Driven. For Digitalization.
Samsung Biologics embraces digitalization to provide next-level client satisfaction

 



#DrivenForLife

  

In celebration of our 10-year anniversary, we showcased a series of branding films that reinforces our mission to be ‘Driven. For Life.’ At Samsung Biologics, we have a unique business DNA embedded in our employees to make the impossible possible and provide seamless service offerings at an expedited speed to ultimately save lives of patients. 

 

In order to provide speedy delivery of molecules to market, we recently launched our newest CDO process platform, S-CellerateTM that offers complete solution with accelerated speed to IND and BLA. Our teams of experts work relentlessly to contribute to saving lives of people worldwide. 

 

Driven. For Life. constantly inspired and driven to enrich human lives
 

 

We are Driven. For Life.
It’s in our DNA
Together We Save Lives
Accelerating your success through our innovative CDO platform | Samsung Biologics premieres S-Cellerate at BPI 2021
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA

 



Driven. For Life.

 


In the year 2022, we will continue with our efforts to take on challenges, demonstrate operational excellence across all value chains, and most importantly save the lives of patients.

 

 

Related Contents


Samsung BIO Insight The Benefit of Speed, Scale & Quality | Explore Samsung Biologics' CMO Strengths

Samsung BIO Insight The Journey to Your Success | Explore Samsung Biologics' CDO Strengths

 

 

 

#2021YearinReview
 

 

2021 was a year to reflect on the decade of immense growth and innovation as we celebrated our 10-year anniversary. We continued with our efforts to supply high-quality biomedicines to patients and embarked upon an important mission to manufacture COVID-19 therapies and mRNA vaccines for both drug product and drug substance to combat the global pandemic to save people’s lives.

 

As the most trusted CDMO partner to our clients, we have accomplished a number of outstanding achievements and here are some of the key highlights that shaped an extraordinary year.

 

 

#TheFutureofBiopharma


At the 2021 JP Morgan Healthcare Conference, we shared our vision for the next decade, unveiling a multi-dimensional business plan for the company with a greater global footprint and continued advancements in future modalities. 

 

By embracing great opportunity ahead of us, we have strived this year to diversify our portfolio to become the global top-tier biopharmaceutical company. 

 

#TheFutureofBiopharma
 

 

Samsung Biologics Shares ‘Vision’ for Next Decade at the 39th Annual JP Morgan Healthcare Conference
John Rim, CEO of Samsung Biologics shares future plans at BIO Digital 2021
CPhI Worldwide 2021 I Infinite Possibilities for the Next Decade
Talking COVID-19 Vaccine Cooperation with John Rim
BBC Storyworks | The Speed of Science 

 

 


#mRNA 


mRNA was without a doubt the most talked about topic this year in turning the tide of the pandemic.

 

We began the supply of Moderna’s COVID-19 vaccine (mRNA 1273) upon securing the large-scale commercial fill-finish manufacturing agreement and successfully obtained Marketing Authorization from Ministry of Food and Drug Safety of Korea within 7 months of signing.

In November, we also announced the collaboration to manufacture GreenLight’s mRNA COVID-19 vaccine candidate at commercial scale, aiming to open the way to make vaccines available to everybody, including patients in lower income countries.

 

With our commitment to save lives by creating greater accessibility to biomedicines worldwide, this year we made an announcement to add messenger RNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022.

 

#mRNA

 

 

Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine
Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing 

 



#ESG

 

This year, sustainability was not just a buzzword – it was our mission and commitment.

 

To create a sustainable future for humanity, we published our first sustainability report, consolidating a roadmap to building a more sustainable environment for all.

In September, we announced the signing of an MOU to participate in the Frontier -1.5D initiative to develop a climate risk management model as part of the 2050 Carbon Neutral Strategy in response to the ongoing challenges associated with global climate change.

 

We also joined leaders across the healthcare system to form a Health Systems Taskforce as part of the Sustainable Markets Initiative hosted by His Royal Highness Prince of Wales in light of COP26. Within the Taskforce, John Rim, CEO of Samsung Biologics, was designated as a champion for the Supply Chains Working Group with a focus on accelerating the net zero transition across the health system’s supply chains by establishing concrete action plans and metrics to assess its environmental impact.

 

We are committed to making sustainability a key component of the way we work and engage with our partners and stakeholders, and will continue to actively partake in this global movement next year.

 

Sustainability Report 2021
 
 

 

Samsung Biologics Issues First Annual Sustainability Report
Sustainable Markets Initiative(SMI) | CEO Message
Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative
Six Korean companies added to Dow Jones Sustainability World Index 

 

 


#Quality


Despite the ongoing spread of COVID-19, we established a robust internal system to stably supply biomedicines to patients. Over the course of this year, we added five global ISO certifications for ISO22301 BCMS(Business Continuity Management System▲ISO45001 Occupational Health and Safety ▲ISO14001 Environmental Management ▲ISO50001 Energy Management ISO9001 Quality Management System.

 

Also amid a time of significant changes to the market dynamics, we proactively implemented innovative digitalized tools into our processes to enhance the client experience. By leveraging our Live Virtual Tour, EQUIS: Enterprise Quality Unified Information System, and virtual exhibition hall, our employees worked tirelessly to improve our service offerings and ultimately provide top-notch quality biomedicines.

 

#Quality
 

 

Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health & Safety, and Environmental Management
Samsung Biologics adds to global ISO certifications with Quality Management System
Driven. For Digitalization.
Samsung Biologics embraces digitalization to provide next-level client satisfaction 

 



#DrivenForLife

  

In celebration of our 10-year anniversary, we showcased a series of branding films that reinforces our mission to be ‘Driven. For Life.’ At Samsung Biologics, we have a unique business DNA embedded in our employees to make the impossible possible and provide seamless service offerings at an expedited speed to ultimately save lives of patients. 

 

In order to provide speedy delivery of molecules to market, we recently launched our newest CDO process platform, S-CellerateTM that offers complete solution with accelerated speed to IND and BLA. Our teams of experts work relentlessly to contribute to saving lives of people worldwide. 

 

Driven. For Life. constantly inspired and driven to enrich human lives
 

 

We are Driven. For Life.
It’s in our DNA
Together We Save Lives
Accelerating your success through our innovative CDO platform | Samsung Biologics premieres S-Cellerate at BPI 2021
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA 

 



Driven. For Life.

 


In the year 2022, we will continue with our efforts to take on challenges, demonstrate operational excellence across all value chains, and most importantly save the lives of patients.

 

 

Related Contents


Samsung BIO Insight The Benefit of Speed, Scale & Quality | Explore Samsung Biologics' CMO Strengths

Samsung BIO Insight The Journey to Your Success | Explore Samsung Biologics' CDO Strengths

 

 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved